Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02549391

Phase 3 Study of KHK7580

Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)

Sponsor: Kyowa Kirin Co., Ltd.

Conditions Secondary Hyperparathyroidism

Interventions KHK7580 KRN1493

Updated 7 times since 2017 Last updated: Mar 23, 2017 Started: Sep 30, 2015 Primary completion: Nov 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Secondary Hyperparathyroidism and is currently completed. Kyowa Kirin Co., Ltd. leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Apr 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jan 2017 — Apr 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan